Ryaltris is a nasal spray. It’s a new drug application by Glenmark Pharma and it will be used to treat allergic rhinitis and other conditions.
Recommended ArticlesView All
World Bipolar Day: Here's why this disease is still a complex affair despite competent therapies
Mar 30, 2023 IST5 Min(s) Read
This Jadavpur University alumnus has created world’s first energy-saving paint and other amazing stuff
Mar 29, 2023 IST4 Min(s) Read
March F&O Series: Nifty 50 falls over 400 points to mark worst series since September
Mar 29, 2023 IST2 Min(s) Read
Learn how to clear US, UK arrival immigration in 10 seconds from Jet's Sanjiv Kapoor
Mar 29, 2023 IST3 Min(s) Read
The drug is going to be marketed and distributed via the US partner Hikma.
The delay in Ryaltris was because they had received a complete response letter (CRL) in June 2019 from the US drug regulator. So, the street was waiting and watching in terms of whether or not they would manage to solve the CRL query successfully and finally see the light of day.
This particular drug, Ryaltris, has been approved in Australia, Poland, Russia, South Africa, Ukraine, Czech Republic, and in April 2021 there was an enabling approval for 17 countries in Europe as well. They have entered into commercial agreements with multiple partners, for example, Hikma in the US, but in the European Union (EU) as well as in Canada where this drug is under review.
This is big news for Glenmark because this particular drug is a new drug application by Glenmark, which finally got the US nod and has been in the works for a while.
Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.